Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 13/20 | 0.56 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18362163 | 0.95 | LOXL2 (0.61) | LOXL2BCL2MCL1MRGPRX4HTR6 | |
| SCHEMBL20337877 | 0.89 | LOXL2 (0.55) | LOXL2BCL2MCL1HTR6 | |
| SCHEMBL18362032 | 0.85 | LOXL2 (0.59) | LOXL2HTR6 | |
| Trifluoroacetic Acid SCHEMBL20337918 | 0.85 | LOXL2 (0.67) | LOXL2 | |
| SCHEMBL18362021 | 0.84 | LOXL2 (0.61) | LOXL2HTR6 | |
| Hydrochloric Acid SCHEMBL20337895 | 0.83 | LOXL2 (0.60) | LOXL2HTR6 | |
| Acetic Acid SCHEMBL20337861 | 0.79 | LOXL2 (0.66) | LOXL2MCL1 | |
| SCHEMBL18361822 | 0.79 | LOXL2 (0.74) | LOXL2 | |
| SCHEMBL20337919 | 0.79 | LOXL2 (0.66) | LOXL2 | |
| SCHEMBL18362073 | 0.77 | LOXL2 (0.74) | LOXL2MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | LOXL2 1/4885BCL2 2303/4885MCL1 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.